



Research Article

Artificial Intelligence's Significance in Diseases with Malignant Tumors

Ruchi Doshi^{1,*}, Kamal Kant Hiran², Murat Gök³, El-Sayed M. El-kenawy⁴, Amr Badr⁵, Mostafa Abotaleb⁶

¹ Department of Computer Science and Engineering, Universidad Azteca, Chalco, Mexico

² Department of Computer Science & Engineering, Sir Padampat Singhanian University, Udaipur, India

³ Department of Computer Engineering, Yalova University, Yalova, Turkey

⁴ Department of Communications and Electronics, Delta Higher Institute of Engineering and Technology, Mansoura, Egypt

⁵ Faculty of Science, School of Science and Technology, University of New England, Armidale, Australia

⁶ Department of System Programming, South Ural State University, Chelyabinsk, Russia

ARTICLE INFO

Article History

Received 11 May 2023

Accepted 5 Jul 2023

Published 11 Jul 2023

Keywords

Artificial intelligence

Tumours

Genetic

Machine learning

Personalized medicine

ABSTRACT

In the field of medicine, artificial intelligence has become a useful tool, particularly in the diagnosis and treatment of disorders with malignant tumours. Deep learning and machine learning algorithms, for example, have significant promise for increasing the precision and effectiveness of tumour diagnosis and treatment. The importance of AI in diseases with malignant tumours is examined in this work, with particular attention paid to its function in medication discovery, therapy prediction, and medical imaging analysis. It also emphasizes the difficulties and restrictions related to the application of AI, such as problems with poor data quality, as well as the requirement for legal and moral considerations. Basically, AI offers exciting possibilities to improve personalized treatment, early detection, and research developments in oncology, but careful consideration must be given to ensure appropriate and successful integration into clinical practice.



1. INTRODUCTION

Recently, artificial intelligence has been used in most areas of life, including in the medical field, especially in examining malignant tumours and improving their detection [1-3]. Artificial intelligence has a role in analysing medical images such as artificial intelligence techniques are used by analysing changes, predictions, and gene expression to analyse large sets of clinical, histological, and genetic data and develop diagnostic models based on artificial intelligence to improve the accuracy of diagnosis [4-6]. Large medical records medical images, and clinical reports can be analysed to discover important patterns and data that can be used to give good results in examining tumours. Health institutions seek to use artificial intelligence methods to analyse large amounts of genetic data and identify characteristics associated with diseases, as well as benefit from it in determining the optimal treatment for each patient based on the genetic information recorded in the hospital or medical clinic management system and distinguishing machine science algorithms in analysing genetic records, predicting the development of disease within the human body, identifying malignant tumours, as well as predicting the patient's response to treatment specified by healthcare workers [7-10]. Besides, AI algorithms combined with new data collection technologies will support tracking people's health and disease status. Moreover, AI systems can revolutionise the way new drugs are researched and developed, enhancing and reducing time in drug research, accelerating the processes of identifying and discovering new molecules, identifying new therapeutic targets and developing new treatments [11][12].

2. TRAINING AI IN DETECTING MALIGNANT TUMOURS

Artificial Intelligence techniques have confirmed the exciting ability to effectively identify and classify malignant tumours through the capabilities of analysing medical images (X-rays, CT scans, and MRIs) [13-15]. These techniques are exploited

*Corresponding author. Email: ruchi.doshi@univ-azteca.edu.mx

in analysing big data with continuous training of machine learning models by specialists in this field. These trained models can then examine recent images to detect any anomalies that might indicate the presence of a tumour in the human body. To increase the precision of tumour diagnosis, AI can also help in the combination of data from many different sources, including genetic data, patient medical histories, and demographic data. AI can deliver more accurate and individualised diagnoses by taking various factors into account. Additionally, AI is able to continuously learn from fresh data and adapt, which will eventually improve the detection and diagnosis of malignant tumours. AI is a useful tool for assisting physicians and researchers in keeping up with the most recent advancements in tumour identification thanks to its adaptive learning capabilities. Trained AI algorithms can determine whether abnormal tumours seen on a CT scan are cancerous. Early detection of these abnormal tumours makes cancer treatment more successful, improves the disease condition, and focuses on patients at greater risk. These algorithms are used to study the behaviour of CT images and identify cancer cells in a large number of patients. This procedure contributes to extracting valuable information from these images that the human eye can catch. In addition, these algorithms have a significant role in detecting breast cancer and diagnosing the disease via X-ray scans. These procedures are critical in customising effective treatment that improves patient outcomes.




Fig. 1. AI for the spotting, diagnosing, and treating of tumours [16].

3. PREDICT RESPONSE TO TREATMENT USING AI TECHNOLOGY

Artificial intelligence technology has the potential to forecast how different medical illnesses will respond to treatment [17][18]. AI systems can identify trends and forecast how a patient will react to a certain treatment by examining vast volumes of patient data. Analysing electronic health records (EHRs) is one method AI can be used to forecast treatment response. The patient's demographics, medical history, lab findings, medication history, and treatment outcomes are all essential pieces of information that can be found in EHRs. Artificial intelligence algorithms have the ability to make predictions by extracting variables associated with treatment outcomes and analysing molecular profiling and genomic data. This prediction is practical for physicians in determining the behaviour of malignant tumours, knowing their ability to respond to the drug, and determining vital and clinical indicators. Artificial intelligence has an influential ability to predict the treatment of diseases and diagnose malignant diseases [20][21]. Prediction is one of the practices of artificial intelligence techniques in determining genetic and clinical characteristics and responses to chemotherapy or other treatments. Moreover, these techniques have been used to predict treatment outcomes for people suffering from depression or psychological anxiety, as well as predict infectious diseases, while providing a report on the most suitable treatment procedure to enhance patient outcomes. According to estimates by the Global Cancer Observatory (Globocan), there are about 19.3 million new cancer cases per year and almost 10 million deaths from this cause worldwide. In fact, oncology is witnessing remarkable progress driven by advanced technologies and innovative methods. Still, there are malignant tumours that are difficult to detect using traditional methods rather than utilising machine learning algorithms. Health organisations have large datasets in the form of images and health records. Using machine learning, they can analyse this

data until they discover patterns and relevant information that even a team of highly qualified professionals would not be able to detect. While AI can provide insightful forecasts, it's critical to remember that medical practitioners should understand these predictions in conjunction with clinical judgment. Instead of replacing medical professionals, artificial intelligence should be viewed as a supportive tool to aid in treatment decisions. Examining patient data from EHRs, genomic data, and molecular profiles, AI technology has the ability to predict the response to treatment. This can aid healthcare specialists in making better decisions and customising therapies for each patient, resulting in improved effects and individualized care.




Fig. 2. EHR in clinical trials [19].

4. PREDICTING GENETIC RISK

Recently, machine learning algorithms have been employed in many studies to predict the incidence of certain diseases based on a person's religious makeup. These algorithms study patterns and correlations that can be applied to predict through approaches trained to find tumour cases. Google DeepMind's AlphaFold is an artificial intelligence program used to predict protein structures and display changes in DNA. This program predicts how genetic changes will affect the protein environment and provides information about potential disease risks. Other programs are being applied to predict genetic diseases, such as DeepMind's AlphaMissense. Modern artificial intelligence programs aim to provide complete details about disease-causing mutations using practices that include a comprehensive review of genetic variants and accurate interpretation. These practices are of great importance in determining the incidence of certain diseases through early detection and prevention methods. Moreover, these practices help doctors determine the severity of the disease, select the appropriate treatment for each case, and help improve patient outcomes. Predicting genetic risks is essential in healthcare, and integrating artificial intelligence helps doctors and healthcare workers diagnose diseases accurately and efficiently. Artificial intelligence provides a safe environment to protect patients' genetic data and not permit it to be tampered with, changed, or stored elsewhere. Artificial intelligence in healthcare has a powerful impact on managing and analysing large amounts of data and information sources optimally. It will assist in automating and improving clinical and organisational processes, improve the ability to make decisions and characterise health conditions more accurately. The primary objective of these technologies is to assist physicians in the decision-making process and determine the patient's needs for medication and the optimal treatment method. The ability of AI algorithms to analyse large amounts of information and find complex patterns will predictably lead to significant improvements at different stages of the healthcare process. Thus, predictive and preventive health can be used to anticipate specific emergencies or crises and design more accurate models for predicting disease risks. This will permit the proposed actions that contribute to reducing the burden of diseases in health systems and recognise individuals most likely to benefit from disease treatment or prevention approaches in the population. Machine learning algorithms can detect signs of lung cancer on computed tomography (CT) up to a year before they are diagnosed with current methods. Researchers hope that utilising machine learning to support lung cancer screening could make the

process faster and more efficient and ultimately assist in diagnosing more patients at an earlier stage. CT scanning is already utilised to detect signs of lung tumours, followed by a biopsy or surgery to confirm whether the tumour is malignant. However, with each scan, an experienced radiologist reviews about 300 images and looks for signs of cancer that may be very small. Trials of CT scans to detect individuals at high risk of lung cancer screening have shown promise but are hampered by the practical problem of having a radiologist check each image, one by one, to decide who requires further testing [22].

5. CONCLUSIONS

Particularly in personalized medicine, AI can be extremely useful in predicting treatment outcomes. AI algorithms are able to pinpoint variables that affect a patient's response to a particular medication by analysing huge quantities of patient information, including genetic and clinical data. Using this data, doctors can create individualized treatment regimens that increase the likelihood of positive outcomes and reduce the use of pointless or inefficient treatments. AI may also help in the creation of novel therapies and medications. AI algorithms can find possible therapeutic targets or forecast the effectiveness of certain substances by analysing enormous volumes of research data and drawing correlations that people might miss. This could hasten the process of drug discovery and eventually result in more precise and strong treatments for conditions characterized by malignant tumours. Although AI has a lot of potential, it is important to recognize its limitations. The accuracy and representativeness of the data used to train AI algorithms are crucial factors. So that, forecasts or the reinforcement of pre-existing prejudices in the healthcare industry are both possible outcomes of biased data and inadequate datasets. To ensure patient safety and privacy, integrating AI into clinical practice will also need to overcome legislative and ethical obstacles. The use of artificial intelligence in diseases with malignant tumours is growing in importance because it presents prospects for better drug development, diagnosis, and treatment. The discipline of oncology can be transformed by utilizing AI technologies to analyse medical imaging, predict outcomes of treatments, and practice personalized medicine. To ensure the appropriate and efficient use of AI in healthcare, however, great consideration must be given to addressing the difficulties and constraints related to its deployment.

Funding

The authors had no institutional or sponsor backing.

Conflicts Of Interest

The author's disclosure statement confirms the absence of any conflicts of interest.

Acknowledgment

The authors extend appreciation to the institution for their unwavering support and encouragement during the course of this research.

References

- [1] A. Escalé-Besa, O. Yélamos, J. Vidal-Alaball, A. Fuster-Casanovas, Q. M. Catalina, et al., "Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care," *Scientific Reports*, vol.13, no.4293, pp.1-14, March 2023. <https://doi.org/10.1038/s41598-023-31340-1>
- [2] M. M. Mijwil, K. K. Hiran, R. Doshi, M. Dadhich, AH. Al-Mistarehi, and I. Bala, "ChatGPT and the Future of Academic Integrity in the Artificial Intelligence Era: A New Frontier," *Al-Salam Journal for Engineering and Technology*, vol. 2, no. 2, pp.116-127, April 2023. <https://doi.org/10.55145/ajest.2023.02.02.015>.
- [3] Y. Kumar, S. Gupta, R. Singla, and Y. Hu, "A Systematic Review of Artificial Intelligence Techniques in Cancer Prediction and Diagnosis," *Archives of Computational Methods in Engineering*, vol.29, pp.2043–2070, September 2021. <https://doi.org/10.1007/s11831-021-09648-w>
- [4] V. Baxi, R. Edwards, M. Montalto, and S. Saha, "Digital pathology and artificial intelligence in translational medicine and clinical practice," *Modern Pathology*, vol.35, no.1, pp.23-32, January 2022. <https://doi.org/10.1038/s41379-021-00919-2>
- [5] J. Calderaro, T. P. Seraphin, T. Luedde, and T. G. Simon, "Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma," *Journal of Hepatology*, vol.76, no.6, pp.1348-1361, June 2022. <https://doi.org/10.1016/j.jhep.2022.01.014>

- [6] G. Ali, M. M. Eid, O. G. Ahmed, M. Abotaleb, A. M. Z. Alaabdin, and B. A. Buruga, "Artificial intelligence in Corneal Topography: A Short Article in Enhancing Eye Care," *Mesopotamian Journal of Artificial Intelligence in Healthcare*, vol.2023, pp.31–34, June 2023. <https://doi.org/10.58496/MJAIH/2023/006>
- [7] M. M. Mijwil, R. Doshi, K. K. Hiran, O. J. Unogwu, and I. Bala, "MobileNetV1-Based Deep Learning Model for Accurate Brain Tumor Classification," *Mesopotamian Journal of Computer Science*, vol.2023, pp:32-41, March 2023. <https://doi.org/10.58496/MJCSC/2023/005>
- [8] O. Elemento, C. Leslie, J. Lundin, and G. Tourassi, "Artificial intelligence in cancer research, diagnosis and therapy," *Nature Reviews Cancer*, vol.21, no.12, pp.747–752, September 2021. <https://doi.org/10.1038/s41568-021-00399-1>
- [9] A. Stenzinger, M. Alber, M. Allgäuer, P. Jurmeister, M. Bockmayr, et al., "Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling," *Seminars in Cancer Biology*, vol.84, pp.129-143, September 2022. <https://doi.org/10.1016/j.semcancer.2021.02.011>
- [10] Z. Dlamini, F. Z. Francies, R. Hull, and R. Marima, "Artificial intelligence (AI) and big data in cancer and precision oncology," *Computational and Structural Biotechnology Journal*, vol.18, pp.2300-2311, 2020. <https://doi.org/10.1016/j.csbj.2020.08.019>
- [11] K. Mak and M. R. Pichika, "Artificial intelligence in drug development: present status and future prospects," *Drug Discovery Today*, vol.24, no.3, pp.773-780, March 2019. <https://doi.org/10.1016/j.drudis.2018.11.014>
- [12] S. Medenica, D. Zivanovic, L. Batkoska, S. Marinelli, G. Basile, et al., "The Future Is Coming: Artificial Intelligence in the Treatment of Infertility Could Improve Assisted Reproduction Outcomes—The Value of Regulatory Frameworks," *Diagnostics*, vol.12, no.12, pp.2979, November 2022. <https://doi.org/10.3390/diagnostics12122979>
- [13] H. Khalid, M. Hussain, M. A. Al Ghamdi, T. Khalid, K. Khalid, et al., "A Comparative Systematic Literature Review on Knee Bone Reports from MRI, X-Rays and CT Scans Using Deep Learning and Machine Learning Methodologies," *Diagnostics*, vol.10, no.8, pp.518, July 2020. <https://doi.org/10.3390/diagnostics10080518>
- [14] M. M. Mijwil, K. Aggarwal, R. Doshi, K. K. Hiran, B. Sundaravadivazhagan, "Deep Learning Techniques for COVID-19 Detection Based on Chest X-ray and CT-scan Images: A Short Review and Future Perspective," *Asian Journal of Applied Sciences*, vol.10, no.3, pp.224-231, July 2022. <https://doi.org/10.24203/ajas.v10i3.6998>
- [15] S. Agarwal, A. S. Yadav, V. Dinesh, K. S. S. Vatsav, K. S. S. Prakash, and S. Jaiswal, "By artificial intelligence algorithms and machine learning models to diagnosis cancer," *Materials Today: Proceedings*, vol.80, 2969-2975, 2023. <https://doi.org/10.1016/j.matpr.2021.07.088>
- [16] M. Ullah, A. Akbar, and G. Yannarelli, "Applications of artificial intelligence in, early detection of cancer, clinical diagnosis and personalized medicine," *Artificial Intelligence in Cancer*, vol.1, no.2, pp.39-44, 2020. <https://doi.org/10.35713/aic.v1.i2.39>
- [17] M. Supriya and V. K. Chattu, "A Review of Artificial Intelligence, Big Data, and Blockchain Technology Applications in Medicine and Global Health," *Big Data and Cognitive Computing*, vol.5, no.3, pp.1-20, September 2021. <https://doi.org/10.3390/bdcc5030041>
- [18] A. Syrowatka, M. Kuznetsova, A. Alsubai, A. L. Beckman, P. A. Bain, et al., "Leveraging artificial intelligence for pandemic preparedness and response: a scoping review to identify key use cases," *npj Digital Medicine*, vol.4, no.96, pp.1-14, 2021. <https://doi.org/10.1038/s41746-021-00459-8>
- [19] EMR vs. EHR: What's the difference?, PRACTO, September 2014. <https://doctors.practo.com/emr-vs-ehr-whats-difference/>
- [20] S. Syed-Abdul, R. Firdani, H. Chung, M. Uddin, M. Hur, et al., "Artificial Intelligence based Models for Screening of Hematologic Malignancies using Cell Population Data," *Scientific Reports*, vol.10, no.4583, pp.1-8, March 2020. <https://doi.org/10.1038/s41598-020-61247-0>
- [21] S. M. Khazaal and H. Maarouf, "Predicting Coronary Artery Disease Utilizing Support Vector Machines: Optimizing Predictive Model," *Mesopotamian Journal of Artificial Intelligence in Healthcare*, vol.2023, pp.21–26, March 2023. <https://doi.org/10.58496/MJAIH/2023/004>
- [22] Artificial intelligence could help diagnose lung cancer a year earlier, *ecancer*, September 2021. <https://ecancer.org/en/news/20877-artificial-intelligence-could-help-diagnose-lung-cancer-a-year-earlier>